Aims: To explore the prognostic and clinicopathological features of glioma with Paxillin (PXN) expression based on a large number of samples. Methods: RNA sequencing data of 325 glioma samples from Chinese Glioma Genome Atlas (CGGA) database were obtained as discovery set. Three additional datasets were further obtained as validation sets. The protein expression pattern of PXN in glioma was measured by IHC. Kaplan-Meier survival and multivariate Cox analysis were used to estimate the survival distributions. Moreover, the functional annotation of PXN was also analyzed. Results: In the discovery set, PXN overexpression was significantly associated with high-grade glioma as well as the higher mortality in survival analysis (log-rank test, P < 0.01). The results of the other validation datasets showed similar findings. PXN also served as an independent prognostic biomarker in glioblastoma patients. Functional assays showed that PXN contributed to glioma cell proliferation and invasion. Conclusion: PXN plays as an oncogene in glioma progression and suggests a new potential biotarget for therapy.
Introduction
Glioblastoma multiforme (GBM), the most common and malignant type of glioma, remains one of the most lethal cancer in center nervous system (CNS) [1, 2] . Despite the advances in combination of resection, chemotherapy, and radiotherapy, the median survival of GBM patients is only about 1 year [3] . The major clinical challenge for GBM therapy is that tumor cells deeply infiltrate into adjacent normal brain tissues and/or migrate to the contralateral cerebral hemisphere at early stage and escape from surgical removal and are relatively resistant to radiotherapy as well as chemotherapy, resulting in tumor recurrence [4, 5] . GBM invasion is the combination of specific proteases that enable the remodeling of extracellular matrix (ECM) component and the extracellular integrin interactions [6] , which are mediated by numerous regulators, including PXN.
PXN, a phosphorylated adaptor protein, plays a critical role in cytoskeletal remodeling and focal adhesion process by recruiting diverse cytoskeleton and signaling proteins into a complex and coordinating the transmission of downstream targets to regulate cell migration and invasion [7] [8] [9] . PXN has been reported to be dysregulated and acts as an oncogene in malignancy progression of many human cancers [10] [11] [12] [13] [14] [15] [16] [17] [18] . However, only limited studies showed that PXN was present in some glioma cell lines [6, 19] , and little was known about the expression pattern of PXN in glioma samples, as well as the clinical features and prognostic value of PXN in glioma. In this study, we evaluated the expression pattern, prognostic value, and biological associations of PXN from CGGA RNA sequencing expression profiling of glioma samples and validated in three other independent datasets. We further demonstrated the functional roles of PXN in glioma cell lines. All these results indicate PXN is a novel prognostic biomarker with potential anti-invasion therapeutic implications in GBM.
Methods

PXN Expression Analysis in Datasets
RNA sequencing expression data and clinical information of 325 glioma samples (109 grade II, 72 grade III, and 144 grade IV samples) from Chinese Glioma Genome Atlas (CGGA) database (http://www.cgga.org.cn) were obtained as the discovery set. The Cancer Genome Atlas (TCGA) RNA sequencing database (http://cancergenome.nih.gov), the whole-genome mRNA expression microarray data of Repository for Molecular Brain Neoplasia Data (REMBRANDT) (http://caintegrator-info.nci.nih. gov/REMBRANDT), and GSE16011 data (http://www. ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16011) were obtained as validation sets. CGGA and TCGA RNA sequencing data were log2-transformed. In the four datasets, only samples with definite WHO classification were included for expression analysis, and only GBM samples with survival data were used for survival analysis (two samples diagnosed as GBM but defined as WHO I grade in REMBRANDT dataset were excluded).
Immunohistochemistry (IHC)
Immunohistochemical staining with streptavidin-biotin immunoperoxidase assay was performed on an independent group of 41 formalin fixed, paraffin-embedded glioma tissues (15 grade II, 12 grade III, 14 grade IV) from CGGA database to detect PXN expression using rabbit anti-human PXN (Abcam, Cambridge, MA, USA, 1:500) primary antibody as previously carried out [20] . The staining score = staining intensity 9 proportion of positively stained tumor cells. High PXN expression was defined as a staining score >4, while low expression was defined as a staining score ≤4. Written informed consents were all obtained from the patients, and the study was approved by the ethics committee of the hospitals involved.
Gene Ontology (GO) Analysis and Gene Set Enrichment Analysis (GSEA) of PXN-Associated Genes
The Pearson correlation analysis of PXN and other genes in whole-genome gene expression profile was performed in CGGA dataset. To detect the biological processes that correlate with PXN expression in glioma, PXN positively correlated genes (r > 0.4, P < 0.01) were analyzed by DAVID (http://david.abcc.ncifcrf.gov/ home.jsp) and GSEA.
Cell Culture and Transfection
Cell culture and transfection were carried out as previously reported [20] . PXN 
Clonogenic and Invasion Assays
The Clonogenic and transwell invasion assays were performed as previously reported [20, 21] .
Western Blot
Western blot was applied as previously carried out [22] . Immunoblot analysis was performed with rabbit anti-PXN polyclonal antibody (Abcam, 1:1500) followed by HRP-conjugated goat antirabbit secondary antibodies. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for loading control.
Statistical Analysis
Statistical analysis was performed using SPSS 16.0 (Armonk, NY, USA), R 3.2.1 and GraphPad Prism 5.0 statistical software (La Jolla, CA, USA). Descriptive statistics were shown as mean AE standard deviation (SD). Student's t-test, chi-square test, and oneway ANOVA test were used to analyze the significance of differences. Overall survival time (OS) was calculated from the date of histological diagnosis until death or the last follow-up. KaplanMeier survival analysis was used to estimate the survival distributions, and the log-rank test was used to assess the statistical significance between stratified survival groups. Patients with lower than median expression level of PXN were defined as low expression, while patients with higher than or equal to the median value were considered as high expression. Univariate and multivariate Cox regression analysis including gender, age, extent of resection, Karnofsky performance status (KPS), isocitrate dehydrogenase1 (IDH1) mutation status, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status, temozolomide (TMZ) treatment, and radiotherapy were used to assess prognostic value of PXN in GBM. A two-sided P value <0.05 was considered statistically significant.
Results
PXN Expression is Associated with Glioma Grade and Shows a Subtype Preference
Firstly, we screened the differentially expressed genes from the CGGA dataset and found that PXN expression was positively correlated with tumor grade (one-way ANOVA, P < 0.01). These results were validated in TCGA, REMBRANDT, and GSE16011 databases ( Figure 1A-D) . To analyze PXN expression pattern in the different molecular subtypes of glioma, we annotated the four datasets using TCGA classification systems by PAM [23, 24] . Based on TCGA subtype classification system, the mesenchymal subtype had the highest PXN expression while the neural subtype showed the lowest, in the four datasets ( Figure 1E-H) . Additionally, IDH1
wild-type glioma samples showed higher PXN expression values than those with mutant IDH1 (Figure 1I -K). These results indicated that PXN had a mesenchymal subtype and IDH1 wild-type preference.
PXN Protein was Measured in an Independent Group of Glioma Samples by IHC
We further detected the protein level of PXN in an independent group of 41 glioma patients from CGGA database by IHC. Similar to PXN RNA expression pattern, PXN protein was low expressed in WHO grade II glioma samples (11 low expressions, four high expressions), comparing with WHO III (four low expressions, eight high expressions) and WHO IV (three low expressions, 11 high expressions) groups (P < 0.013, chi-square test) (Figure 2A , B). Thus, PXN expression was elevated according to the malignancy of glioma in protein level.
High PXN Expression Confers a Poor Prognosis in GBM Patients
The association of PXN expression with prognosis of GBM patients was investigated through Kaplan-Meier survival curve analysis with a log-rank test of 138 GBM patients in CGGA dataset.
Patients with high PXN expression had a significantly worse overall survival time in contrast to those with low PXN expression (P < 0.05) ( Figure 2C ). Furthermore, similar results were also observed in TCGA and GSE16011 validation sets (P < 0.05, P < 0.01, respectively) ( Figure 2D ,E). Although it was not statistically significant in REMBRANDT dataset, overall survival days in high PXN group still showed a decreased trend compared with low group (median OS: high group 360 days, low group 540 days, P = 0.0867) ( Figure 2F ).
PXN is an Independent Prognostic Biomarker for GBM Patients
To further determine the prognostic value of PXN in GBM patients, a univariate Cox regression analysis was employed. As shown in Table 1 , high PXN expression was shown to be a risk factor for GBM patients [P = 0.017, HR = 1.677, 95% confidence interval (CI): 1.099-2.558]. Additionally, some other factors including age, MGMT methylation status, TMZ treatment, KPS score, extent of resection, and radiotherapy were all significantly associated with the overall survival time of GBM patients. Next, we performed multivariate Cox proportional hazards analysis incorporating PXN expression, age, MGMT methylation state, TMZ treatment, KPS score, extent of resection, and radiotherapy. The analysis revealed that PXN was an independent prognostic factor for the overall survival of GBM patients. Taken together, these results imply that PXN might be a novel prognostic biomarker for GBM patients. motion, and migration ( Figure 3A) . The KEGG pathway analysis denoted focal adhesion ( Figure 3B ). And the GSEA analysis showed the similar results ( Figure 3C,D) . These analyses indicate that PXN might have an essential role on glioma cell proliferation and invasion.
PXN Promotes Glioma Cell Proliferation and Invasion
To explore the functional role of PXN in glioma, we first detected PXN protein levels in H4, LN229, U87, U251 glioma cell lines, as shown in Figure 4A ; H4 had the lowest expression level while U87 had the highest. Then, PXN overexpressing vector was employed to elevate PXN expression in H4 cells ( Figure 4B ), and PXN small interference RNA (siRNA) was used to silence PXN expression in U87 cells ( Figure 4C ). Invasion and clonogenic assays were performed to evaluate the function of PXN in glioma cell lines, and the gain-of-function assay in H4 cells indicated that ectopic of PXN promoted cell invasion and proliferation ( Figure 4D,E) , while loss-of-function assay in U87 cells showed that antagonism of PXN expression suppressed the invasive ability of cells, as well as the formation of clones ( Figure 4F ,G).
Discussion
GBM contributes to about 50% of gliomas [25] , which has an inevitable recurrence for its highly invasion behavior that tumor cells diffusely infiltrating into the adjacent normal brain tissues during the early stage of disease. Tumor migration and invasion is a complex and multistep process and contains the surrounding ECM component remodeling, morphological polarization, membrane extension, the formation of cell substratum attachments, contractile force and traction, and the release of attachments [26] . During this process, cell attachments to substratum play crucial role, which is mediated by coordinating signals from ECM components [27] , integrin family [28] , focal adhesion-linked molecules, and the actin cytoskeleton [29] . Among these regulators, we focused on PXN, a focal adhesionassociated protein [30] , which functions as an adaptor protein through interactions with integrin family numbers, growth factors, and cell surface receptors to regulate downstream gene expression, matrix organization, cell proliferation, motility, and migration [30] [31] [32] [33] . Consistently, in this study, we found that PXN expression was positively correlated with tumor grade in mRNA profiling of four independent datasets, as well as PXN protein expression difference which was measured by IHC from an independent validation set of samples. The above results indicate both PXN RNA and protein were associated with tumor malignancy, which has been reported in other cancers [10, 12, [14] [15] [16] [17] .
Besides, PXN can combine with several oncogene to mislead the normal adhesion and growth factor signaling pathways which results in uncontrolled cell proliferation, migration, and invasion [32, [34] [35] [36] . Additionally, phosphorylation of PXN can activate ERK signaling pathway, which further increases the association of focal adhesion kinase (FAK) with PXN to induce cell migration and invasion [13, [37] [38] [39] . In this study, the biological roles of PXN in gliomas were evaluated by in silico and in vitro studies, where a positive correlation of PXN expression with a series of tumor oncogenes, driving cell proliferation, mitosis, and invasion, including TGF-ß1, MAPK, and PLK family members, was observed. Functional assays showed that reduction of PXN expression significantly suppressed U87MG cells proliferation and invasion, while ectopic PXN expression promoted H4 cells proliferation and invasion. All these results are in concordance with the previous reports that PXN is an oncogene in tumor progression. PXN was reported to be regulated by TGF-ß1, which further promoted malignant astrocytoma cell spreading, attachment, and adhesion [19] . And phosphorylated PXN might contribute to TMZ treatment resistant [40] .
PXN has been found to be an oncogene and with prognostic value in various malignant human carcinomas [10] [11] [12] [13] [14] [15] [16] [17] [41] [42] [43] [44] . Similarly in this study, we found that GBM patients with higher expression of PXN had a worse survival than those with lower PXN expression. It remained to be an independent prognostic marker for GBM patients in multivariate Cox regression analysis.
The relationship between clinical features and PXN expression was not yet clear, and a better understanding of the expression pattern and functional role of PXN in glioma progressive process may provide better diagnosis, prognosis of glioma patient, as well as the development of personalized therapeutics to improve the clinical outcomes.
Conclusion
In conclusion, our study showed that the expression level of PXN increased with the ascending grade of glioma. PXN was preferentially expressed in IDH1 wild-type patients, mesenchymal subtype of TCGA classification. Moreover, it conferred a worse overall survival and could act as an independent prognostic biomarker in GBM patients. Finally, we demonstrated that PXN played as an oncogene in GBM cells. All of these results suggest that PXN is a novel biomarker and could be a potential target for GBM treatment.
